内镜治疗与手术切除治疗早期胃癌患者的癌症特异性死亡率相当
基于监测、流行病学和最终结果数据库,纳入1998至2014年诊断为Tis或T1aN0M0浅表性胃癌并接受内镜治疗(n=786)或手术(n=2577)的患者,比较特征与结局。内镜治疗使用比例从1998-2000年的15.1%升至2013-2014年的39.0%。中位随访59个月,内镜治疗组与手术组的5年癌症特异性生存率分别为99%和95%;多因素校正后,两组胃癌特异性死亡率无显著差异(HR 1.42;95%CI 0.91-2.23;P=0.12)。
要点
- 内镜治疗浅表性胃癌的使用比例从1998-2000年的15.1%升至2013-2014年的39.0%。
- 内镜治疗组与手术组的5年癌症特异性生存率分别为99%和95%。
- 校正临床因素后,两组胃癌特异性死亡率无显著差异(HR 1.42;95%CI 0.91-2.23;P=0.12)。
核心结论
- 1998至2014年间,浅表性胃癌的内镜治疗使用呈增加趋势。
- 接受内镜治疗与手术的患者长期癌症特异性死亡率相当。
研究设计与样本
- 基于监测、流行病学和最终结果数据库的 population-based 研究,纳入1998至2014年诊断为Tis或T1aN0M0浅表性胃癌的患者。
- 内镜治疗组786例,手术组2577例;采用多因素logistic回归分析内镜治疗相关因素,并用多因素Cox比例风险模型比较生存。
主要发现
- 内镜治疗使用比例从1998-2000年的15.1%升至2013-2014年的39.0%。
- 与手术相比,内镜治疗更常用于年龄较大、女性、白种人、病变位于近端胃、病变局限于黏膜层(Tis vs T1a)及病变较小的患者。
- 中位随访59个月(四分位距31-102个月);内镜治疗组与手术组的5年总生存率分别为57%和76%,5年癌症特异性生存率分别为99%和95%。
- 校正临床因素后,内镜治疗组与手术组的胃癌特异性死亡率无显著差异(HR 1.42;95%CI 0.91-2.23;P=0.12)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Endoscopic therapy is used commonly for superficial gastric cancer with very low risk of metastasis to the lymph nodes. However, limited population-based studies from the West have evaluated long-term outcomes of patients who received endoscopic therapy vs surgery. METHODS: We used the Surveillance Epidemiology and End Results database to identify and compare features and outcomes of patients who underwent endoscopic therapy (n = 786) or surgery (n = 2577) for Tis or T1aN0M0 superficial gastric cancer, diagnosed from 1998 to 2014. Multivariate logistic regression was performed to identify factors associated with endoscopic therapy. Overall survival and gastric cancer-specific survival times were compared after we controlled for covariates. RESULTS: Use of endoscopic therapy increased from 15.1% of cases in 1998 to 2000 to 39.0% of cases in 2013 to 2014. Endoscopic therapy was used more frequently in patients who were older, female, or Caucasian, or with lesions that were located in the proximal stomach or were limited in depth (Tis vs T1a) and size, compared with surgery. The median follow-up time was 59 months (interquartile range, 31-102 mo). Percentages of 5-year overall and cancer-specific survival were 57% and 99% in the endoscopic therapy group and 76% and 95% in the surgery group. After we adjusted for clinical factors using a multivariate Cox proportional hazards model, we found no significant difference in gastric cancer-specific mortality between patients who received endoscopic therapy vs surgery (hazard ratio, 1.42; 95% CI, 0.91-2.23; P = .12). CONCLUSIONS: In an analysis of a large population database, we found an increased trend in endoscopic therapy for superficial gastric cancer compared with surgery from 1998 through 2014. Patients who received endoscopic therapy vs surgery had comparable long-term cancer-specific mortality.
引用
- Pourmousavi MK, Wang R, Kerdsirichairat T, et al. Comparable Cancer-Specific Mortality of Patients With Early Gastric Cancer Treated With Endoscopic Therapy vs Surgical Resection. Clin Gastroenterol Hepatol. 2020. PMID: 32389885. doi:10.1016/j.cgh.2020.04.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。